Introduction
As the compromised patient population continues to increase, the incidence of serious nosocomial infections caused by Pseudomonas aeruginosa has risen significantly. 1 The importance of P. aeruginosa urinary tract infections is underscored by the latest nosocomial infection survey (December 1996) from the Centers for Disease Control which lists P. aeruginosa as the fourth most common pathogen (11.2%) isolated from the urine of intensive care unit patients over the past 10 years. 2 The current standard empirical treatment of suspected pseudomonal infections involves the use of a -lactam including imipenem/cilastatin or fluoroquinolones such as ciprofloxacin. 3 Recently, however, there has been worldwide concern over the emergence of multiple drug resistant strains of P. aeruginosa. 4 Clinafloxacin, a novel pyrrolidinyl fluoroquinolone currently in clinical trials, shows excellent activity against P. aeruginosa in vitro. 5 In this study, a deep-seated chronic P. aeruginosa renal abscess model was used to evaluate the potential therapeutic potency of clinafloxacin compared with current clinically useful anti-pseudomonal agents. 
Materials and methods

Bacterial strain
The strain of P. aeruginosa (PA-13) used in this study was a typically sensitive clinical isolate taken from the Parke-Davis culture collection. It was chosen on the basis of its inherent ability to establish a reproducible kidney abscess model in mice. Culture identification was confirmed by standard microbiological methods.
Antimicrobial agents
Clinafloxacin was synthesized by the Chemistry Department at Parke-Davis Pharmaceutical Research (Ann Arbor, MI, USA). Ciprofloxacin was obtained from Miles Laboratories (West Haven, CT, USA). Imipenem/cilastatin was obtained from Merck (West Point, PA, USA) and ceftazidime was acquired from Glaxo (Greenford, UK).
Animals
All tests were done using 18-22 g female mice (Charles River Laboratories, Portage, MI, USA). These studies were approved by the Institutional Animal Care and Use Committee (Parke-Davis Pharmaceutical Research).
Determination of MICs
MICs were determined according to the guidelines of the National Committee for Clinical Laboratory Standards. Agents and Chemotherapy. 8 Briefly, on day 1, mice were pretreated intravenously with 20 mg/kg of carrageenan to induce a mild renal pathology. On day 8, these mice were challenged intravenously with approximately 5 10 7 cfu of P. aeruginosa. The culture was grown overnight at 35°C on Tryptic Soy Agar (TSA, Difco, Detroit, MI, USA) and suspended in Tryptic Soy Broth (Difco) before injection. Drug dosing began on day 11 and the mice were treated twice daily for 5 days. Clinafloxacin and ciprofloxacin were administered by the oral route, while all other drugs were given subcutaneously. A 3 day drug washout period was used to minimize any inhibitory effect on colony proliferation due to drug carry-over. The mice were then killed and their kidneys removed surgically and evaluated for residual bacteria count compared with untreated controls. Each kidney was homogenized in physiological saline with a Brinkman Polytron homogenizer. Duplicate 0.1 mL aliquots of saline dilutions of these homogenates were plated on TSA and then incubated for 48 h at 35°C. Colony counts were done and the geometric mean cfu/g was then calculated. A reduction of 3 logs between treated kidneys and untreated controls was considered significant.
Mouse blood concentrations
Mouse blood concentrations of clinafloxacin and ciprofloxacin were estimated by microbiological assay of heart blood samples of uninfected mice at different time points following doses of 50 mg/kg by the oral route. Escherichia coli Kp (Dainippon Pharmaceutical Company, Osaka, Japan) was used as the assay organism. 9 Pharmacokinetic parameter values were estimated by standard noncompartmental analysis of mean concentration-time data.
Results
The differences in geometric mean cfu/g of kidney between treated and untreated mice are presented in Table I . Clinafloxacin was the most effective compound tested, reducing bacterial numbers per gram of kidney by 4 logs when dosed at 50 mg/kg and about 3 logs when dosed at 12.5 mg/kg. Clinafloxacin doses of 3.1 mg/kg achieved a 2 log decrease in bacterial counts. Ciprofloxacin was considerably less effective with doses of 200 mg/kg, reducing bacterial counts per gram of kidney by the same magnitude as 50 mg/kg doses of clinafloxacin. Ceftazidime, the current drug of choice for pseudomonal pyelonephritis, 3 and imipenem/cilastatin were weakly active with 50 mg/kg doses, reducing bacterial counts by 1 log.
The percentage of kidneys cleared of detectable levels of bacteria by each drug is shown in Table II . Following 50 mg/kg doses of clinafloxacin, 88% of the kidneys were completely cleared, while 56% were cleared at a dose of 12.5 mg/kg. No other drug tested produced complete bacterial eradication in 50% of the kidneys at the highest dose tested.
Comparative pharmacokinetic results showed peak mouse blood concentrations of 6.1 and 2.3 mg/L for clinafloxacin and ciprofloxacin, respectively, following a 50 mg/kg single oral dose. Maximum blood levels were achieved at 0.5 h for both drugs. Half-lives were 1.2 h for clinafloxacin and 0.7 h for ciprofloxacin. The area under the curve for clinafloxacin (8.9 mg.h/L) was three times that of ciprofloxacin.
Discussion
An important difference between this model and the pyelonephritis model described by Fernandes et al. 10 is 
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the delayed treatment regimen in the former. During the 72 h interval between inoculation and treatment, a deeply entrenched abscess is allowed to develop. 6 Because the abscess is encapsulated, it acts as a physical barrier to drugs and is relatively intractable to antimicrobial therapy.
In previous studies defining this model, the lack of detectable viable bacteria in the blood, liver, spleen and lungs confirmed that this infection was localized and not systemic. The chronicity of this infection was also documented previously by showing that 80% of the mice persisted with renal abscesses for at least 20 days. 6 In summary, the increasing incidence of serious nosocomial P. aeruginosa infections and the recent emergence of strains resistant to current therapy, mean that new effective anti-pseudomonal agents are greatly needed. In this study clinafloxacin, a novel fluoroquinolone currently in clinical trials, was clearly the most effective antibacterial tested against a chronic deep-seated P. aeruginosa infection. These results suggest that clinafloxacin is potentially very useful for managing serious pseudomonal infections in humans.
